Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

IMDX Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Insight Molecular Diagnostics Inc.NASDAQ: IMDX

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$405.05M, compared with -$357.21M a year earlier.

Context

  • Retained earnings amounted to 1001.9% of total assets at the end of Q1 FY2026, up 410.1 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -13.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$405.05M-1.1% QoQ
Last fiscal yearDec 2025
-$400.76M-14.3% YoY
Year agoMar 2025
-$357.21M-13.4% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.4%——
1 year-14.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(400.76M) USD
Year-over-year change
-14.3%

Retained Earnings vs competitors

How IMDX compares with its peers on the latest reported figures

  • IMDX's Mar 2026 retained earnings of -$405.05M is the 3rd highest of the 10 companies compared; the peer median is -$616.88M.
  • Its year-over-year change of -13.4% is the 5th highest of 10, against a peer median of -15.7%.
  • Retained earnings amounts to 1001.9% of total assets for IMDX, versus a peer median of 412.0%.
IMDX Competitors Peer median
Retained Earnings for IMDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OABIOmniAb, Inc.Mar 2026-$173.89M -45.4%—59.2%
PEPGPepGen Inc.Mar 2026-$378.88M -25.6%—242.4%
IMDXInsight Molecular Diagnostics Inc.Mar 2026-$405.05M -13.4%—1001.9%
MISTMilestone Pharmaceuticals Inc.Mar 2026-$456.67M -17.6%—235.7%
CDXSCodexis, Inc.Mar 2026-$615.48M -5.5%—475.8%
ARMPArmata Pharmaceuticals, Inc.Mar 2026-$616.88M -84.5%—883.8%
PRLDPrelude Therapeutics IncorporatedMar 2026-$693.45M -12.6%—579.6%
CCCCC4 Therapeutics, Inc.Mar 2026-$763.82M -15.7%—232.3%
IVVDInvivyd, Inc.Mar 2026-$995.88M -8.5%—412.0%
SGMOSangamo Therapeutics, Inc.Mar 2026-$1.66B -8.0%—2765.4%
Peer median (excluding IMDX) -$616.88M-15.7%—412.0%

Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.95M19.99M9.43M8.64M11.58M
Short-term Investments904K433K000
Net Receivables1.44M2.01M484K1.61M1.13M
Inventory304K00410K446K
Other Current Assets2.94M2.12M782K1.1M2.15M
Total Current Assets39.14M25.54M10.7M11.76M15.31M
Property, Plant & Equipment (Net)8.37M10.85M5.44M2.76M2.82M
Goodwill18.68M0000
Intangible Assets61.72M61.63M56.6M14.61M0
Long-term Investments0001.7M607K
Tax Assets00000
Other Non-current Assets31.65M2.07M2.16M4.26M7.03M
Total Non-current Assets120.42M74.56M64.19M23.32M10.45M
Total Assets159.56M100.09M74.89M35.08M25.76M
Account Payables1.81M1.25M953K2.28M2.54M
Short-term Debt1.31M0000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.71M4.43M4.01M2.17M2.89M
Total Current Liabilities14.12M12.11M7.19M7.28M12.08M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities76.68M45.66M45.03M37.71M43.46M
Total Non-current Liabilities80.23M48.39M47.23M40.08M45.15M
Total Liabilities94.35M60.5M54.42M47.36M57.22M
Common Stock252.95M294.93M310.3M338.24M369.21M
Retained Earnings(187.77M)(260.68M)(289.88M)(350.54M)(400.76M)
Accumulated OCI37K39K49K21K86K
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity65.22M39.59M20.47M(12.27M)(31.46M)
Total Debt5.68M3.54M2.87M3.66M3.5M
Net Debt(27.27M)(16.45M)(6.56M)(4.97M)(8.09M)

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Intrinsic Alpha fair value

Locked

Current Price

$1.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.